NetMind.AI plans to start NMT buyback in the future to enhance the utility of tokens
According to BlockBeats news, on October 28, NetMind.AI CEO Kai Zou posted on the social media platform to announce the recent progress and future prospects of the project:
1. Continuous innovation of products and functions: As always, we will continue to upgrade new functions for our products and always stand at the forefront of technology. The newly designed website will be launched soon.
2. Expansion of customer base and strategic partners: More customers have been added, more cooperation has been reached with leading technology companies, consulting work has increased, and AI models have been further optimized.
3. Team expansion: The team is growing rapidly. A dedicated business development team has been established and we continue to recruit professionals in the fields of research engineers, product development and business development.
4. Improvement of research work: There has been a significant improvement in research output, and more research work is transformed into more innovative functions and cutting-edge technologies, which NetMind will exclusively implement and apply.
5. Establish the NetMind program: Provide more support to startups, more NMT computing resources will be used for their research and development, and the entire ecosystem is expected to gain benefits and achievements in the future.
6. Enhance the utility of the token: Simple and clear, it is the buyback plan. Wider use of NMT is planned through the NetMind initiative.
7. NetMind Agent Platform Coming Soon: All agents and multi-agent systems will run on NetMind Power, leveraging NMT enhancements and enabling integration capabilities in decentralized infrastructure.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go
Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.
RBA Minutes: Case for rates to act promptly to keep inflation expectations anchored
Crypto prices
More
